IDO1 and hepatocellular carcinoma: Overall, the Authors’ findings reveal that NLG919/PI-FVIOs can induce a potent antitumor immune response by disrupting the IDO pathway and activating immunogenic cell death, offering a promising therapeutic avenue for hepatocellular carcinoma treatment (Wang et al., 2024).